Nigella 5 in the Treatment of SARS COV2 (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

October 30, 2021

Study Completion Date

December 31, 2021

Conditions
SARS-CoV2 Infection
Interventions
DRUG

Nigella

"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."

DRUG

Placebo

"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."

Trial Locations (2)

4054

HU Sahloul, sousse, Tunisia, Sousse

Unknown

Riadh Boukef, Sahloul

All Listed Sponsors
lead

Hôpital Universitaire Sahloul

OTHER

NCT04914767 - Nigella 5 in the Treatment of SARS COV2 (COVID-19) | Biotech Hunter | Biotech Hunter